Back To Schedule
Thursday, September 23 • 9:30am - 10:00am
Inefficiency of the TRIPS Agreement’s Article 31bis Mechanism: The Bolivia-Biolyse Case

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Feedback form is now closed.

Article 31bis, the first amendment to TRIPS Agreement, which entered into force in January 2017, aimed at giving effect to Doha Declaration’s Paragraph 6 flexibility. Since March 2021, Biolyse Pharma – a Canadian company - has been trying to use the Article 31bis mechanism to manufacture COVID vaccines. In May 2021, Biolyse signed an agreement with Bolivia to provide COVID vaccines subject to grant of compulsory licenses under the Article 31bis mechanism. This presentation endeavours to critically evaluate the effectiveness of this mechanism with a special focus on Bolivia-Biolyse case study.

Thursday September 23, 2021 9:30am - 10:00am UTC